Market Analysis
Merck’s Stock Rises Amid New Cancer Treatment Drug Breakthrough
MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by 49%.
MSD's new injectable Keytruda formulation offers similar effectiveness to the intravenous version, potentially halving treatment time.
Merck's wider drug moat and acquisition spree makes it a safer bet but VKTX can be the next LLY.
Which companies are positioned for greater growth?